Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bullinger

Showing results (131-140 of 385) with videos related to

Pageof 39
Sort By:
Immunity|December 2, 2015
PI3 Kinase and FOXO1 Transcription Factor Activity Differentially Control B Cells in the Germinal Center Light and Dark ZonesSandrine Sander, Van Trung Chu, Tomoharu Yasuda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17)Lars Bullinger, Richard F Schlenk, Marlies Götz, et al.
Blood|December 24, 2013
Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patientsNicolas Rapin, Frederik Otzen Bagger, Johan Jendholm, et al.
Oncology Research and Treatment|April 7, 2025
Quality of Life of Cancer Patients in Routine Clinical Care Using the Example of Checkpoint Inhibition Therapy: A Delphi ConsensusPhilipp Ivanyi, Bernd Alt-Epping, Lars Bullinger, et al.
The Journal of Experimental Medicine|January 2, 2013
The cell fate determinant Llgl1 influences HSC fitness and prognosis in AMLFlorian H Heidel, Lars Bullinger, Patricia Arreba-Tutusaus, et al.
Annals of Hematology|January 7, 2017
Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapyJan K Hiller, Claudia Schmoor, Verena I Gaidzik, et al.
Acta Haematologica|May 5, 2025
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trialPhilipp le Coutre, Andreas Burchert, Susanne Saußele, et al.
Neurosurgical Review|March 8, 2017
The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional studyKatrin Nickel, Mirjam Renovanz, Jochem König, et al.
Oncoimmunology|May 10, 2019
Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancerLivius Penter, Kerstin Dietze, Julia Ritter, et al.
Leukemia & Lymphoma|March 11, 2017
Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changesStephan R Bohl, Anna Dolnik, Thomas Jensen, et al.
Pageof 39

Showing results (131-140 of 385) with videos related to

Sort By:
Pageof 39
Immunity|December 2, 2015
PI3 Kinase and FOXO1 Transcription Factor Activity Differentially Control B Cells in the Germinal Center Light and Dark ZonesSandrine Sander, Van Trung Chu, Tomoharu Yasuda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17)Lars Bullinger, Richard F Schlenk, Marlies Götz, et al.
Blood|December 24, 2013
Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patientsNicolas Rapin, Frederik Otzen Bagger, Johan Jendholm, et al.
Oncology Research and Treatment|April 7, 2025
Quality of Life of Cancer Patients in Routine Clinical Care Using the Example of Checkpoint Inhibition Therapy: A Delphi ConsensusPhilipp Ivanyi, Bernd Alt-Epping, Lars Bullinger, et al.
The Journal of Experimental Medicine|January 2, 2013
The cell fate determinant Llgl1 influences HSC fitness and prognosis in AMLFlorian H Heidel, Lars Bullinger, Patricia Arreba-Tutusaus, et al.
Annals of Hematology|January 7, 2017
Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapyJan K Hiller, Claudia Schmoor, Verena I Gaidzik, et al.
Acta Haematologica|May 5, 2025
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trialPhilipp le Coutre, Andreas Burchert, Susanne Saußele, et al.
Neurosurgical Review|March 8, 2017
The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional studyKatrin Nickel, Mirjam Renovanz, Jochem König, et al.
Oncoimmunology|May 10, 2019
Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancerLivius Penter, Kerstin Dietze, Julia Ritter, et al.
Leukemia & Lymphoma|March 11, 2017
Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changesStephan R Bohl, Anna Dolnik, Thomas Jensen, et al.
Pageof 39